Prolonged Response to First-Line Erlotinib for Advanced Lung Adenocarcinoma

Journal of Experimental and Clinical Cancer Research - United Kingdom
doi 10.1186/1756-9966-27-59
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Successful Rechallenge With Gefitinib for an Initial Erlotinib-Responder With Advanced Lung Adenocarcinoma

Tuberculosis and Respiratory Diseases
PulmonaryInfectious DiseasesRespiratory Medicine
2011English

Cost-Effectiveness of First-Line Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer Unsuitable for Chemotherapy

BMJ Open
Medicine
2015English

Real-World Experience of Afatinib as a First-Line Therapy for Advanced EGFR Mutation-Positive Lung Adenocarcinoma

Oncotarget
Oncology
2017English

P3.13-19 Surgery for cIIIB Lung Adenocarcinoma After Response to Erlotinib, Survival and Management of Postoperative Oligoprogressions

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Egfr Test-Guided Erlotinib Versus Chemotherapy for First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Budget Impact Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

P3.01-104 EGFR-RAD51 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-47 Clinical Characteristics and Outcome for Patients With Advanced Lung Adenocarcinoma Treated With First-Line Pemetrexed Plus Platinum

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Sensitizing EGFR Mutation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy